##  [China: Revised Drug Approval Access & Publication of Latest Approved Drug List](/index%2ephp/mandate/china-revised-drug-approval-access-publication-of-latest-approved-drug-list) 

December 9, 2025

The National Medical Products Administration (NMPA) has updated its drug approval and certificate access process, improving transparency and digital accessibility for pharmaceutical stakeholders. The latest approved drug list (effective 03-Dec-2025) includes a wide range of traditional Chinese medicines and modern formulations from major domestic manufacturers.

**Key Highlights:**

- Digital Certificate Access Enhanced: 
    - Since 01-Nov-2022, individuals facing administrative penalties can still access electronic drug approval documents via the NMPA Government Service Portal.
- Newly Approved Drug List Published: 
    - Includes traditional Chinese medicines, chemical formulations, and modern pharmaceutical products.
    - Features products from multiple companies including Shanghai Shangyao Xinyi, Beijing Taide Pharmaceutical, and others.
- Improved Tracking & Transparency: 
    - Each product is assigned a unique registration number and approval validity period, strengthening regulatory traceability.
- Industry Impact: 
    - Reflects growing participation of local and international companies in China’s pharmaceutical market.
    - Supports wider availability of treatment options across therapeutic areas.



[Consult Now](/webform/consult%0A?url=https://preprod.freyrsolutions.com/index%2ephp/markdownify/node/11945)



Source

<https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20251209164150194.html>

 

 

Select Mandate HA

[NMPA](/index%2ephp/mandate-by-ha/nmpa)

 

Select Mandate Function

[Regulatory Affairs](/index%2ephp/mandate-by-function/regulatory-affairs)